Meek David D. — SEC insider filings
SEC reporting owner CIK 1555337. 28 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2020-10-06 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 10 filings — 26,995 shares, $689,903 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 9,080 shares @ $21.25 ($192,950) in uniQure N.V., filed 2026-11-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| uniQure N.V. (QURE) | Director | 13 | — | 8 legs · 19,200 sh · $368,636 | 14 |
| Mirati Therapeutics, Inc. (MRTX) | Chief Executive Officer, Director | 5 | — | 2 legs · 7,795 sh · $321,267 | 6 |
| Entasis Therapeutics Holdings Inc. (ETTX) | Director | 5 | — | — | 11 |
| Cullinan Therapeutics, Inc. (CGEM) | Director | 3 | — | — | 3 |
| Fusion Pharmaceuticals Inc. (FUSN) | Director | 2 | — | — | 2 |
Insider filings — Meek David D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | uniQure N.V. (QURE) | Sale (S): 9,080 @ $21.25 | EDGAR |
| 2026-06-18 | 4 | Cullinan Therapeutics, Inc. (CGEM) | Grant/award (A): 25,319 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | uniQure N.V. (QURE) | Grant/award (A): 7,550 @ $0 · Sale (S): 1,993 @ $27.06 · Grant/award (A): 13,980 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | uniQure N.V. (QURE) | Sale (S): 2,112 @ $14.45 | EDGAR |
| 2025-06-16 | 4 | Cullinan Therapeutics, Inc. (CGEM) | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | uniQure N.V. (QURE) | Grant/award (A): 7,970 @ $0 · Grant/award (A): 15,630 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | uniQure N.V. (QURE) | Grant/award (A): 8,080 @ $0 · Grant/award (A): 15,840 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | uniQure N.V. (QURE) | Sale (S): 2,229 @ $5.12 | EDGAR |
| 2024-06-04 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Disposition to issuer (D): 34,000 (derivative) | EDGAR |
| 2024-05-16 | 4 | Cullinan Therapeutics, Inc. (CGEM) | Grant/award (A): 15,618 (derivative) @ $0 | EDGAR |
| 2023-10-16 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | uniQure N.V. (QURE) | Grant/award (A): 8,700 @ $0 · Sale (S): 2,290 @ $18.85 · Grant/award (A): 17,060 (derivative) @ $0 | EDGAR |
| 2023-03-01 | 4 | uniQure N.V. (QURE) | Sale (S): 389 @ $19.71 | EDGAR |
| 2023-01-24 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 89,379 @ $0 · Grant/award (A): 151,233 (derivative) @ $0 | EDGAR |
| 2023-01-19 | 4 | Mirati Therapeutics, Inc. (MRTX) | Sale (S): 3,179 @ $42.38 | EDGAR |
| 2022-12-21 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 35,425 @ $0 · Sale (S): 4,616 @ $40.41 | EDGAR |
| 2022-07-11 | 4 | Entasis Therapeutics Holdings Inc. (ETTX) | Code (U): 22,000 @ $2.20 · Disposition to issuer (D): 27,500 @ $2.20 · Other (J): 17,307 (derivative) @ $0 · Other (J): 11,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | uniQure N.V. (QURE) | Grant/award (A): 9,080 @ $0 · Grant/award (A): 17,810 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | uniQure N.V. (QURE) | Sale (S): 602 @ $16.70 | EDGAR |
| 2022-02-28 | 4 | uniQure N.V. (QURE) | Grant/award (A): 1,534 @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Entasis Therapeutics Holdings Inc. (ETTX) | Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 11,538 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Grant/award (A): 5,769 (derivative) | EDGAR |
| 2022-01-19 | 4 | Entasis Therapeutics Holdings Inc. (ETTX) | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2022-01-18 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 34,057 @ $0 · Grant/award (A): 56,433 (derivative) @ $0 | EDGAR |
| 2021-09-24 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 150,300 (derivative) @ $0 | EDGAR |
| 2021-04-02 | 4 | Entasis Therapeutics Holdings Inc. (ETTX) | Grant/award (A): 22,000 @ $0 | EDGAR |
| 2021-03-04 | 4 | uniQure N.V. (QURE) | Sale (S): 505 @ $37.50 | EDGAR |
| 2021-03-01 | 4 | uniQure N.V. (QURE) | Grant/award (A): 2,382 @ $0 · Grant/award (A): 4,107 (derivative) @ $0 | EDGAR |
| 2020-10-06 | 4 | Entasis Therapeutics Holdings Inc. (ETTX) | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1555337 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs